Novartis expands digital focus with Amblyotech deal

After dropping its commercialization deal with Pear last year, Novartis is reinforcing its strategic commitment to digital therapeutics through the acquisition of Amblyotech.

The takeout gives Novartis AG (NYSE:NVS; SIX:NOVN) access to Amblyotech Inc.’s digital technology to treat amblyopia, or “lazy eye,” which pairs interactive games with 3-D glasses to optimize visual acuity using both eyes...